Filtered By:
Source: Clinical Cancer Research
Therapy: Endocrine Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
CONCLUSIONS: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.
PMID: 30314968 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 12, 2018 Category: Cancer & Oncology Authors: Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CL Tags: Clin Cancer Res Source Type: research
